Antibacterial medicinal chemistry – what can we design for?

References

• Ardal C, Balasegaram M, Laxminarayanan R, et al. Antibiotic development - economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267-274.
   Google Scholar
• Bloomberg [Internet]. 2018. Superbugs Win Another Round as Big Pharma Leaves Antibiotics.[cited 2019 Dec 24]. Available from: https://www.bloomberg.com/news/articles/2018-07-13/superbugs-win-another-round-as-big-pharma-leaves-antibiotics
   Google Scholar
• Theuretzbacher U, Outterson K, Engel A, et al. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18:275-285.
   Google Scholar
• REVIVE-GARDP [Internet]. [cited 2019 Dec 24]. Available from: https://revive.gardp.org/.
   Google Scholar
• IMI:ND4BB [Internet]. [cited 2019 Dec 24]. Available from: https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb.
   Google Scholar
• Helmholtz-HZI [Internet]. [cited 2019 Dec 24]. Available from: https://www.helmholtz-hzi.de/en/news-events/news/view/article/complete/working-together-in-the-fight-against-tuberculosis-and-malaria-1/.
   Google Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24:892.
   PubMed Web of Science ®Google Scholar
• Singh SB, Young K, Silver LL. What is an “ideal” antibiotic? Discovery challenges and path forward. Biochem Pharmacol. 2017;133:63–73.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40.
   PubMed Web of Science ®Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.
   PubMed Web of Science ®Google Scholar
• Tommasi R, Brown DG, Walkup GK, et al. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov. 2015;14:529–542.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–519.
   PubMed Web of Science ®Google Scholar
• Peláez F. The historical delivery of antibiotics from microbial natural products - can history repeat? Biochem Pharmacol. 2006;71:981–990.
   PubMed Web of Science ®Google Scholar
• Kirst HA. Developing new antibacterials through natural product research. Expert Opin Drug Discov. 2013;8:479–493.
   PubMed Web of Science ®Google Scholar
• Singh SB, Young K, Miesel L. Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther. 2011;9:589–613.
   PubMed Web of Science ®Google Scholar
• Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688–702.e13.
   PubMed Web of Science ®Google Scholar
• Silver LL. Appropriate targets for antibacterial drugs. Cold Spring Harb Perspect Med. 2016;6:1–7.
   Web of Science ®Google Scholar
• McPhillie MJ, Cain RM, Narramore S, et al. Computational methods to identify new antibacterial targets. Chem Biol Drug Des. 2015;85:22–29.
   PubMed Web of Science ®Google Scholar
• Engle EC, Manes SH, Drlica K. Differential effects of antibiotics inhibiting gyrase. J Bacteriol. 1982;149:92–98.
   PubMed Web of Science ®Google Scholar
• Wang G, Divall S, Radovick S, et al. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat Chem Biol. 2015;311:587–596.
   Google Scholar
• Tonge PJ. Drug-target kinetics in drug discovery. ACS Chem Neurosci. 2018;9:29–39.
   PubMed Web of Science ®Google Scholar
• Poulsen BE, Yang R, Clatworthy AE, et al. Defining the core essential genome of pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2019;116:10072–10080.
   PubMed Web of Science ®Google Scholar
• Fabret C, Hoch JA. A two-component signal transduction system essential for growth of bacillus subtilis: implications for anti-infective therapy. J Bacteriol. 1998;180:6375–6383.
   PubMed Web of Science ®Google Scholar
• Martin PK, Li T, Sun D, et al. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol. 1999;181:3666–3673.
   PubMed Web of Science ®Google Scholar
• Liu M, Hanks TS, Zhang J, et al. Defects in ex vivo and in vivo growth and sensitivity to osmotic stress of group A Streptococcus caused by interruption of response regulator gene vicR. Microbiology. 2006;152:967–978.
   PubMed Web of Science ®Google Scholar
• Heath RJ, Rock CO. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem. 1995;270:26538–26542.
   PubMed Web of Science ®Google Scholar
• Balemans W, Lounis N, Gilissen R, et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature. 2010;463:2009–2011.
   Web of Science ®Google Scholar
• Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature. 2009;458:83–86.
   PubMed Web of Science ®Google Scholar
• Raetz CRH, Lipopolysaccharide Endotoxins WC. Annu. Rev Biochem. 2002;71:635–700.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593–656.
   PubMed Web of Science ®Google Scholar
• Loho T, Dharmayanti A. Colistin: an antibiotic and its role in multiresistant Gram-negative infections. Acta Med Indones. 2015;47:157–168.
   PubMed Web of Science ®Google Scholar
• Vaara M. Polymyxin derivatives that sensitize Gram-negative bacteria to other antibiotics. Molecules. 2019;24:249.
   Web of Science ®Google Scholar
• Vaara M, Siikanen O, Apajalahti J, et al. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother. 2010;54:3341–3346.
   PubMed Web of Science ®Google Scholar
• Corbett D, Wise A, Langley T, et al. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob Agents Chemother. 2017;61:1–10.
   Web of Science ®Google Scholar
• Domalaon R, Idowu T, Zhanel GG, et al. Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens? Clin Microbiol Rev. 2018;31:1–45.
   Web of Science ®Google Scholar
• Acosta-Gutiérrez S, Ferrara L, Pathania M, et al. Getting drugs into gram-negative bacteria: rational rules for permeation through general porins. ACS Infect Dis. 2018;4:1487–1498.
   PubMed Web of Science ®Google Scholar
• Masi M, Réfregiers M, Pos KM, et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat Microbiol. 2017;2:2020.
   Web of Science ®Google Scholar
• Pagès JM, James CE, Winterhalter M. The porin and the permeating antibiotic: A selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol. 2008;6:893–903.
   PubMed Web of Science ®Google Scholar
• Hancock REW, Farmer SW, Li Z, et al. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob Agents Chemother. 1991;35:1309–1314.
   PubMed Web of Science ®Google Scholar
• Atanaskovic I, Kleanthous C. Tools and approaches for dissecting protein bacteriocin import in gram-negative bacteria. Front Microbiol. 2019;10:1–12.
   PubMed Web of Science ®Google Scholar
• Page MGP. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis. 2019;69:S529–S537.
   PubMed Web of Science ®Google Scholar
• Giedyk M, Jackowska A, Równicki M, et al. Vitamin B 12 transports modified RNA into E. coli and S. Typhimurium cells. Chem Commun. 2019;55:763–766.
   PubMed Web of Science ®Google Scholar
• De Geyter J, Smets D, Karamanou S, et al. Inner membrane translocases and insertases. In: Kuhn Aeditor. Bacterial cell walls membrane. Cham: Springer International Publishing; 2019. p. 337–366.
   Google Scholar
• Richter MF, Drown BS, Riley AP, et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature. 2017;545:299–304.
   PubMed Web of Science ®Google Scholar
• Lin J, Sahin O, Michel LO, et al. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun. 2003;71:4250–4259.
   PubMed Web of Science ®Google Scholar
• LJ P. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19:382–402.
   PubMed Web of Science ®Google Scholar
• Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev. 2015;28:337–418.
   PubMed Web of Science ®Google Scholar
• Passalacqua KD, Charbonneau M-E, O’Riordan MXD. Bacterial metabolism shapes the host–pathogen interface. Microbiol Spectr. 2016;4:15–41.
   Web of Science ®Google Scholar
• Hall BG, Barlow M. Evolution of the serine β-lactamases: past, present and future. Drug Resist Updat. 2004;7:111–123.
   PubMed Web of Science ®Google Scholar
• Past BK. Present perspective on β-lactamase inhibitors. Antimicrob Agents Chemother. 2018;62:1–20.
   Google Scholar
• Spaulding A, Takrouri K, Mahalingam P, et al. Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: test case for a general approach to improving whole cell Gram-negative activity. Bioorg Med Chem Lett. 2017;27:5310–5321.
   PubMed Web of Science ®Google Scholar
• Kourtesi C, Ball AR, Huang -Y-Y, et al. Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J. 2013;7:34–52.
   PubMedGoogle Scholar
• Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: an Overview. Cold Spring Harb Perspect Med. 2016;6:a025247.
   PubMed Web of Science ®Google Scholar
• Tooke CL, Hinchliffe P, Bragginton EC, et al. β-Lactamases and β-Lactamase inhibitors in the 21st century. J Mol Biol. 2019;431:3472–3500.
   PubMed Web of Science ®Google Scholar
• Parker EN, Drown BS, Geddes EJ, et al. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens. Nat Microbiol. 2020;5:67-75.
   Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61:235–237.
   PubMed Web of Science ®Google Scholar
• Sarathy JP, Via LE, Weiner D, et al. Extreme drug tolerance of mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. 2018;62:1–11.
   Web of Science ®Google Scholar
• Smith DA, Rowland M. Intracellular and intraorgan concentrations of small molecule drugs: theory, uncertainties in infectious diseases and oncology, and promise. Drug Metab Dispos. 2019;47:665–672.
   PubMed Web of Science ®Google Scholar
• Varma MVS, Feng B, Obach RS, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844–4852.
   PubMed Web of Science ®Google Scholar
• Ito S, Ando H, Ose A, et al. Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. J Pharm Sci. 2013;102:3294–3301.
   PubMed Web of Science ®Google Scholar
• Dave RA, Morris ME. Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humans. Drug Metab Dispos. 2015;43:73–81.
   PubMed Web of Science ®Google Scholar
• Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents. 2013;42:289–293.
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol. 2007;7:498–504.
   PubMed Web of Science ®Google Scholar
• Muller M, Pena A, Derendorf H. Minireview-issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–1453.
   PubMed Web of Science ®Google Scholar
• Azeredo FJ, Dalla Costa T, Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet. 2014;53:205–212.
   PubMed Web of Science ®Google Scholar
• Dahyot C, Marchand S, Couet W, et al. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob Agents Chemother. 2005;49:2356–2361.
   PubMed Web of Science ®Google Scholar
• Araki H, Ogake N, Tsuneda R, et al. Muscle distribution of antimicrobial agents after a single intravenous administration to rats. Drug Metab Pharmacokinet. 2002;17:237–244.
   PubMedGoogle Scholar
• Marchand S, Chauzy A, Dahyot-Fizelier C, et al. Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacol Res. 2016;111:201–207.
   PubMed Web of Science ®Google Scholar